COVID-19 Neuro Databank (NeuroCOVID)

The COVID-19 Neuro Databank (NeuroCOVID) was created to collect detailed, curated and harmonized de-identified cross-sectional data from a large diverse observational cohort of adults with new or worsened neurological conditions associated with illness caused by SARS-CoV-2 infection. It was meant to serve as a uniquely valuable scientific resource by overcoming typical limitations of siloed small local patient cohorts. Twenty U.S. and five international study sites were recruited for diversity and inclusion of previously under-represented patient populations, including a wide geographical distribution, academic and non-academic sites, urban and non-urban locations, and patients of different ages, disease severity and covariates seen by a variety of clinical specialists. A cohort of non-pregnant adult patient records at each site was identified, each describing patients with a new or worsened neurological condition associated with a COVID-19 infection confirmed by testing between January 1, 2020 and May 2025. Deidentified data were abstracted from medical records using standardized common data elements and case report forms. Data are included from demographics, medical history, COVID-19-related symptoms and signs, hospitalization and testing case report forms. The database was carefully enhanced in response to feedback from site investigators and evolving scientific interest in post-acute conditions and their timing. The database contains 4303 inpatient and outpatient patient visit records, from patients across all adult age groups with a large variety of acute and post-acute neurological conditions including: psychiatric/metal health, headache, stroke, CNS infection/inflammatory disease, seizures, dementia, neuromuscular system, pain syndrome, movement disorders, traumatic brain injury, toxic metabolic encephalopathy, brain or spinal cord tumors, myelopathy, neuro-ophthalmologic, and dysautonomia. Key strengths of NeuroCOVID database are: 1) Depth of phenotyping, including almost 1700 demographic and clinical variables: 2) data regarding relatively rare conditions; 3) specific inclusion criteria and common variables across all clinical sites; 4) diverse patient population; 5) agile and efficient responsiveness to evolving understanding of this illness; and 6) data on post-acute symptoms from early in the pandemic. Limitations are: 1) Populations other than nonpregnant adults are not included: 2) cross sectional design limits longitudinal data on course of illness; 3) data from EMR only and does not include other data sources. Additional data on illness timing may be available upon request from the PI contact information provided.]]>
Adult Patients (18 years old and over): • Diagnosed with SARS-CoV-2 infection on or after January 1, 2020, by laboratory testing AND • New neurological condition or worsening of pre-existing neurological conditions associated with SARS-CoV-2 infection ]]>
Data included from January 2020 through May 2025.]]>